Cost-effectiveness of PARP inhibitors in malignancies: A systematic review

OBJECTIVES: Poly (ADP-ribose) polymerase inhibitor (PARPi) have become a mainstay for the treatment of BRCA-mutant malignancies. PARPis are likely to be more effective but also bring an increase in costs. Thus, we aimed at evaluating the cost effectiveness of PARPis in the treatment of malignancies....

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Haiying, He, Chaoneng, Tong, Yinghui, Fang, Qilu, Mi, Xiufang, Chen, Lingya, Xin, Wenxiu, Fang, Luo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754183/
https://www.ncbi.nlm.nih.gov/pubmed/36520958
http://dx.doi.org/10.1371/journal.pone.0279286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754183/
https://www.ncbi.nlm.nih.gov/pubmed/36520958
http://dx.doi.org/10.1371/journal.pone.0279286

Ejemplares similares